Press Room

Press Release / Aug 30, 2012

Hovione Announces the Appointment of Mike Ironside, PhD as General Manager TTC

Loures, Portugal, 30 August 2012 - Hovione today announced the appointment of Dr. Mike Ironside as General Manager, TTC in New Jersey. Dr. Ironside was previously with GSK in the UK and AMRI and most recently with Anacor Pharmaceuticals, both in USA, where he held the position of Vice President of Chemical Manufacture and Development.

“This is a key appointment at an important time for Hovione. We are certain that Dr. Ironside’s leadership qualities combined with his relevant experience in chemical and analytical process development, scale-up from Pilot Plant to full commercial scale will enable us to further strengthen and enlarge our US operations in New Jersey and add new approaches to solve our customers’ most challenging problems.”, said Dr. Thomas Eisele, Vice President Corporate Research & Development.

“I am excited and honoured about this new opportunity to lead the Hovione team in New Jersey. Throughout my career I have had a great respect for Hovione, a company that is recognized as world leader in pharmaceutical manufacture and particle design. I am looking forward to helping further enhance the TTC’s established reputation for offering our customers’ integrated solutions for any molecule “said Dr. Ironside.

Dr. Ironside brings over 20 years of experience in the development and scale-up of APIs from lead candidate optimization through to NDA submission and commercialization. He also brings extensive experience in the management of scientific and operational teams in Biotech and Contract Research Organization (CRO) environments.

Dr. Ironside is a member of the Royal Society of Chemistry in Great Britain and a member of the editorial board of the ACS Journal Organic Process Research and Development. He trained as an organic chemist at Dundee University, Dundee, UK, and holds a PhD in organic chemistry from the same University.

About Hovione

Hovione is a global company with over 50 years’ experience in Active Pharmaceutical Ingredient and Drug Product Intermediate development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. Hovione offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit www.hovione.com  or contact Marketing & Communication, Isabel Pina, + 351 21 982 9362, e-mail:ipina@hovione.com 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024